The CATALYST trial evaluated mifepristone, a glucocorticoid receptor antagonist, for HbA1c lowering in adults with hypercortisolism and inadequately controlled type 2 diabetes.

Read Healio’s in-depth coverage of the CATALYST study . Enlarge

A total of 136 participants with hypercortisolism and inadequately controlled type 2 diabetes were randomly assigned 2:1 to mifepristone (Korlym, Corcept Therapeutics)

or placebo. The mean age was 63 years, 61% were men and mean baseline HbA1c was 8.55%.

At 24 weeks, mifepristone was associated with greater declines in HbA1c. HbA1c levels decreased from 8.62% to 7.12% in the mifepristone group vs. 8.41% to 8.36% in the placebo group. Mifepristone was also associated with reductions in body weight, BMI and waist circumference and an increase in bl

See Full Page